John Mulligan, Ph.D.

Dr. John Mulligan is the Founder and CEO of Bonum Therapeutics. He is a scientist and executive with 30 years of experience in research management, drug discovery, technology innovation and company formation. He was the Founder and CEO of Good Therapeutics until it was acquired by Roche in 2022. Prior to Good he founded Glycostasis, where he invented a glucose-responsive insulin technology and sold the company to Eli Lilly. As the Director of Genomics at Darwin Molecular he pioneered a genetic approach to target discovery that yielded an osteoporosis drug target. Romosozumab, an antibody to this target, is approved in the US, Europe and Japan for the treatment of osteoporosis.